The success of Ozempic and Wegovy has turned Novo Nordisk into Europe’s biggest company. But Eli Lilly’s newest version of GLP-1 drugs, Zepbound, could take a big bite out of the market. Amid rising obesity rates and increasing demand for weight-loss solutions, valuations for both pharmaceutical giants are soaring.